Discover the causes behind fatty liver disease, a condition affecting 25% of adults worldwide, and learn simple lifestyle ...

TVB-3567 is the Company's second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 SAN MATEO, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences ...

TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitor First-in-human Phase 1 trial initiation planned in 2025 ...

The deadly Non-Alcoholic Fatty Liver Disease is reaching epidemic proportions in India, with three out of 10 adults and ...

Objectives Carotid intima–media thickness (CIMT) is a measurement for subclinical atherosclerosis and has been associated with overall cardiovascular diseases, especially in type 2 diabetes mellitus ...

Hepatic steatosis, often triggered by non-alcoholic fatty liver disease (NAFLD), is a leading cause of liver dysfunction globally, affecting approximately 30% of the population.

1Division of Life Sciences and Medicine, Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, ...

Key Laboratory of Environmental Remediation and Ecological Health, Ministry of Industry and Information Technology, School of Environmental and Biological Engineering, Nanjing University of Science ...

found that CSN6 binds to both FBXW7β and FASN, and antagonizes the activity of FBXW7β by enhancing its self-ubiquitination and degradation, thereby preventing FBXW7β-mediated ubiquitination and ...

Adipocytes absorb and accumulate dietary fat molecules to feed their fat vacuoles, while Plikus observed that LCs had a relatively higher concentration of saturated fatty acid chains, which are ...